AI Article Synopsis
- Methylxanthines, including caffeine and aminophylline/theophylline, are used to treat apnea of prematurity in infants born between 23-35 weeks gestation.
- A study comparing 144 cases found that caffeine treatment had a shorter median duration (11 days) compared to aminophylline/theophylline (17 days) and resulted in lower rates of tachycardia (8.3% vs. 34.4% for heart rates ≥160 bpm).
- Overall, caffeine showed greater efficacy and fewer side effects, particularly for male infants and those born at less than 30 weeks gestation.
Article Abstract
Background: Methylxanthines (caffeine; aminophylline/theophylline) are commonly used for apnea of prematurity (AOP) treatment. We aimed to compare the efficacy and adverse effects of caffeine and aminophylline/theophylline.
Methods: A retrospective case-control gestational age-matched study investigates patients born between January 2017 and December 2018, 23-35 weeks gestation with birth weights >500 g treating AOP with caffeine or aminophylline/theophylline.
Results: There were 144 cases (48 in caffeine group and 96 in aminophylline/theophylline group). The median treatment durations were 11 and 17 days in caffeine and aminophylline/theophyllinegroup ( = 0.002). When tachycardia is defined as heart rate ≥160 bpm, the rates were 8.3 and 34.4% in caffeine and control group ( = 0.001). When tachycardia is defined as 10 bpm over baseline heart rate, the rates were 41.7 and 63.5% in caffeine and aminophylline/theophylline group ( = 0.01). Stratified by gestational age and sex, significant reductions in tachycardia rates with caffeine than with theophylline were limited to male infants and infants born at <30 weeks gestation.
Conclusions: For apnea treatment, caffeine has greater efficacy and fewer tachycardia than aminophylline/theophylline, especially in male infants and infants born at <30 weeks gestation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907829 | PMC |
| http://dx.doi.org/10.3389/fped.2022.817624 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Doxapram for the prevention and treatment of apnea in preterm infants.
Cochrane Database Syst Rev
October 2023
Paediatrics, Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
Background: Apnea of prematurity is a common problem in preterm infants that may have significant consequences on their development. Methylxanthines (aminophylline, theophylline, and caffeine) are effective in the treatment of apnea of prematurity. Doxapram is used as a respiratory stimulant in cases refractory to the methylxanthine treatment.
View Article and Find Full Text PDFDeveloping and testing a clinical care bundle incorporating caffeine citrate to manage apnoea of prematurity in a resource-constrained setting: a mixed methods clinical feasibility study protocol.
Implement Sci Commun
July 2023
Department of Paediatrics, Aga Khan University, Nairobi, Kenya.
Background: Apnoea of prematurity (AOP) is a common condition among preterm infants. Methylxanthines, such as caffeine and aminophylline/theophylline, can help prevent and treat AOP. Due to its physiological benefits and fewer side effects, caffeine citrate is recommended for the prevention and treatment of AOP.
View Article and Find Full Text PDFSpecific Premature Groups Have Better Benefits When Treating Apnea With Caffeine Than Aminophylline/Theophylline.
Front Pediatr
February 2022
Department of Pediatrics, National Taiwan University Children Hospital, National Taiwan University College of Medicine, Taipei, Taiwan.
Article Synopsis
- Methylxanthines, including caffeine and aminophylline/theophylline, are used to treat apnea of prematurity in infants born between 23-35 weeks gestation.
- A study comparing 144 cases found that caffeine treatment had a shorter median duration (11 days) compared to aminophylline/theophylline (17 days) and resulted in lower rates of tachycardia (8.3% vs. 34.4% for heart rates ≥160 bpm).
- Overall, caffeine showed greater efficacy and fewer side effects, particularly for male infants and those born at less than 30 weeks gestation.
Ligand-dependent conformational changes in the clamp region of the cardiac ryanodine receptor.
J Biol Chem
February 2013
Libin Cardiovascular Institute of Alberta, Department of Physiology and Pharmacology and Department of Biochemistry and Molecular Biology, University of Calgary, Calgary, Alberta T2N 4N1, Canada.
Global conformational changes in the three-dimensional structure of the Ca(2+) release channel/ryanodine receptor (RyR) occur upon ligand activation. A number of ligands are able to activate the RyR channel, but whether these structurally diverse ligands induce the same or different conformational changes in the channel is largely unknown. Here we constructed a fluorescence resonance energy transfer (FRET)-based probe by inserting a CFP after residue Ser-2367 and a YFP after residue Tyr-2801 in the cardiac RyR (RyR2) to yield a CFP- and YFP-dual labeled RyR2 (RyR2(Ser-2367-CFP/Tyr-2801-YFP)).
View Article and Find Full Text PDFProtective effects of methylxanthines on hypoxia-induced apoptotic neurodegeneration and long-term cognitive functions in the developing rat brain.
Neonatology
November 2010
Department of Pediatrics, School of Medicine, Dokuz Eylul University, Inciralti, Izmir, Turkey.
Aminophylline is widely used in the management of premature apnea. The methylxanthines aminophylline, theophylline and caffeine are nonspecific inhibitors of adenosine receptors. There are no proven effects of methylxanthines on acute brain injury and long-term cognitive functions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!